journal
MENU ▼
Read by QxMD icon Read
search

Clinical Advances in Hematology & Oncology: H&O

journal
https://www.readbyqxmd.com/read/27673291/correction-bruton-s-tyrosine-kinase-inhibitors-in-chronic-lymphocytic-leukemia-and-lymphoma
#1
(no author information available yet)
An article in the July 2016 issue, "Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma" by Gaurav Varma, MSPH, Tyler P. Johnson, MD, and Ranjana H. Advani, MD, described ONO/GS-4059 as a "reversible" inhibitor of BTK when it is in fact an "irreversible" inhibitor. We have made the correction to pages 546 and 552 of the online version at www.hematologyandoncology.net. Many thanks to an astute reader for pointing out the error. This corrects the article pmid:27379948.
September 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27673290/the-role-of-high-dose-melphalan-and-autologous-stem-cell-transplant-in-the-rapidly-evolving-era-of-modern-multiple-myeloma-therapy
#2
Peter M Voorhees, Saad Z Usmani
The advent of the immunomodulatory drugs thalido-mide, lenalidomide, and pomalidomide; the proteasome inhib-itors bortezomib, carfilzomib, and ixazomib; the histone deacet-ylase inhibitor panobinostat; and the monoclonal antibodies elotuzumab and daratumumab has led to dramatic improvements in outcomes for patients with multiple myeloma. Along with progress in nontransplant therapy have come questions regarding the continued role of high-dose melphalan (HDM) supported by autologous stem cell transplant (ASCT) in the treatment of multiple myeloma...
September 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27673289/the-status-of-poly-adenosine-diphosphate-ribose-polymerase-parp-inhibitors-in-ovarian-cancer-part-2-extending-the-scope-beyond-olaparib-and-brca1-2-mutations
#3
Rowan E Miller, Jonathan A Ledermann
Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors have shown clinical activity in epithelial ovarian cancer, leading both the US Food and Drug Administration (FDA) and the European Medicines Agency to approve olaparib for tumors characterized by BRCA1 and BRCA2 mutations. However, it is becoming increasingly evident that tumors that share molecular features with BRCA-mutant tumors-a concept known as BRCAness-also may exhibit defective homologous recombination DNA repair, and therefore will respond to PARP inhibition...
September 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27673288/cytoreductive-nephrectomy-for-metastatic-renal-cell-carcinoma
#4
Lisly J Chery, Jose A Karam, Christopher G Wood
The incidence of renal cell carcinoma is increasing, with up to one-third of patients presenting with metastatic disease. Combination therapy is used to prolong survival in patients with metastatic renal cell carcinoma, which carries a poor prognosis. Although two pivotal phase 3 trials have demonstrated the efficacy of immunotherapy after cytoreductive nephrectomy for metastatic disease, for now, targeted therapy has replaced immunotherapy as the preferred systemic treatment in these patients. Two ongoing phase 3 trials are evaluating the role of cytoreductive nephrectomy prior to targeted therapy...
September 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27673287/management-of-brain-metastases-in-breast-cancer
#5
Carey K Anders
No abstract text is available yet for this article.
September 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27673286/zika-and-the-safety-of-the-us-blood-supply
#6
Michael P Busch
No abstract text is available yet for this article.
September 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27673285/special-concerns-for-survivors-of-prostate-cancer
#7
Andrew C Peterson
No abstract text is available yet for this article.
September 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27673284/emerging-treatment-options-for-carcinoid-syndrome
#8
Matthew H Kulke
No abstract text is available yet for this article.
September 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27673283/consolidation-therapy-after-autologous-stem-cell-transplant-in-relapsed-refractory-hodgkin-lymphoma
#9
Craig H Moskowitz
No abstract text is available yet for this article.
September 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27673282/the-importance-of-dose-optimization-prior-to-initiation-of-a-registration-trial
#10
Nam A Rahman
No abstract text is available yet for this article.
September 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27673281/letter-from-the-editor-from-2003-to-today
#11
Bruce D Cheson
No abstract text is available yet for this article.
September 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27487107/trifluridine-tipiracil-and-regorafenib-new-weapons-in-the-war-against-metastatic-colorectal-cancer
#12
Benjamin A Weinberg, John L Marshall, Mohamed E Salem
Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States. Approximately 20% of patients have metastatic disease at diagnosis, and a vast number of these patients die within 5 years. The advent of modern chemotherapeutics has improved median overall survival for these patients; nonetheless, we must keep striving for better outcomes. Trifluridine/tipiracil (TAS-102) and regorafenib are agents newly approved by the US Food and Drug Administration that show promise in the treatment of metastatic colorectal cancer...
August 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27487106/the-status-of-poly-adenosine-diphosphate-ribose-polymerase-parp-inhibitors-in-ovarian-cancer-part-1-olaparib
#13
Rowan E Miller, Jonathan A Ledermann
Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors have shown promising clinical activity in epithelial ovarian cancer. Following the observation in vitro that PARP inhibition is synthetically lethal in tumors with BRCA mutations, PARP inhibition has become the first genotype-directed therapy for BRCA1- and BRCA2-associated ovarian cancer. However, it is becoming clear that PARP inhibition also may have clinical utility in cancers associated with defects or aberrations in DNA repair that are unrelated to BRCA mutations...
August 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27487105/moving-beyond-monotherapy-in-the-immunotherapeutic-arena-prospects-for-combination-therapies-in-lung-cancer
#14
Scott J Antonia
No abstract text is available yet for this article.
August 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27487104/improving-clinical-trial-design-through-quantitative-pharmacology
#15
Michael L Maitland
No abstract text is available yet for this article.
August 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27487103/recent-advances-in-the-management-of-myelofibrosis
#16
Ruben A Mesa
No abstract text is available yet for this article.
August 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27487102/highlights-in-kidney-cancer-from-the-2016-american-society-of-clinical-oncology-annual-meeting
#17
(no author information available yet)
No abstract text is available yet for this article.
August 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27487101/sorafenib-in-combination-with-transarterial-chemoembolization-for-the-treatment-of-hepatocellular-carcinoma
#18
Jean-Francois H Geschwind, Julius Chapiro
No abstract text is available yet for this article.
August 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27487100/are-we-ready-for-precision-medicine-in-acute-myeloid-leukemia
#19
Gail J Roboz
No abstract text is available yet for this article.
August 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/27487099/the-role-of-talimogene-laherparepvec-t-vec-in-the-age-of-checkpoint-inhibitors
#20
Robert H Andtbacka
No abstract text is available yet for this article.
August 2016: Clinical Advances in Hematology & Oncology: H&O
journal
journal
40386
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"